Company: PMVP
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030414
Chunk: 53

Company: PMV Pharmaceuticals, Inc.
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1A
Chunk 53
---
 our existing cash and cash equivalents due to market conditions. The failure of a bank, or other adverse conditions in the financial or credit markets impacting financial institutions at which we maintain balances, could adversely impact our liquidity and financial performance. There can be no assurance that our deposits in excess of the FDIC or other comparable insurance limits will be backstopped by the United States, or that any bank or financial institution with which we do business will be able to obtain needed liquidity from other banks, government institutions or by acquisition in the event of a failure or liquidity crisis.

Our future capital requirements depend on many factors, including: 

•the scope, progress, results and costs of researching and developing our current product candidates or any future product candidates we choose to pursue, and conducting preclinical studies and clinical trials, including our clinical trials of rezatapopt; 

 29

•the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates or any future product candidates; 

•the number and characteristics of any additional product candidates we develop or acquire; 

•the timing and amount of any milestone, royalty and/or other payments we are required to make pursuant to any future license or collaboration agreements; 

•the cost of manufacturing our product candidates or any future product candidates and any products we successfully commercialize; 

•the cost of building a sales force in anticipation of product commercialization; 

•the cost of commercialization activities of our product candidates, if approved for sale, including marketing, sales and distribution costs; 

•our ability to establish future collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; 

•any product liability or other lawsuits related to our products; 

•the expenses needed to attract, hire and retain skilled personnel; 

•the costs associated with being a public company; 

•the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio; 

•the timing, receipt and amount of sales of any future approved products; and 

•the impact of a global pandemic or other public health emergencies on our operations, which may exacerbate the magnitude of the factors discussed above.

We do not have any committed external source of funds and adequate additional financing may not be available to us on acceptable terms, or at all. In addition, our ability to raise additional capital may be adversely impacted by potential worsening global economic conditions, inflation expectations, rising interest rates and the disruptions to